---
title: "Rhythm Pharmaceuticals CFO Sells Shares"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275183443.md"
description: "Rhythm Pharmaceuticals' CFO, Smith Hunter C, sold 6,628 shares of common stock on February 4th and 5th, 2026, under a Rule 10b5-1 plan. The shares were sold at prices between $104.34 and $108.08, totaling $702,744. After the sale, he retains ownership of 125,537 shares. The transaction was reported in SEC Form 4."
datetime: "2026-02-06T23:40:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275183443.md)
  - [en](https://longbridge.com/en/news/275183443.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275183443.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275183443.md) | [繁體中文](https://longbridge.com/zh-HK/news/275183443.md)


# Rhythm Pharmaceuticals CFO Sells Shares

Rhythm Pharmaceuticals' Chief Financial Officer, Smith Hunter C, sold a total of 6,628 shares of common stock on February 4th and 5th, 2026, under a Rule 10b5-1 plan adopted on February 28, 2025. The transactions were executed at weighted average prices ranging from $104.34 to $108.08, resulting in a total sale amount of $702,744. Following these transactions, Smith Hunter C directly owns 125,537 shares of the company.

Reporter Name

Smith Hunter C

Relationship

Chief Financial Officer

Type

Sell

Amount

$702,744

SEC Filing

Form 4

SEC Filing: RHYTHM PHARMACEUTICALS, INC. \[ RYTM \] - Form 4 - Feb. 06, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### 相关股票

- [Rhythm Pharma (RYTM.US)](https://longbridge.com/zh-CN/quote/RYTM.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)

## 相关资讯与研究

- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/zh-CN/news/278556054.md)
- [Spruce Biosciences 2025 net loss narrows, secures $50 mln funding](https://longbridge.com/zh-CN/news/278380208.md)
- [Oragenics receives HREC approval, begins Phase IIa ONP-002 site initiation in Australia](https://longbridge.com/zh-CN/news/278776483.md)
- [Clene 2025 net loss narrows as expenses fall](https://longbridge.com/zh-CN/news/278880252.md)
- [CSP International Publishes Disclosure on V2D Création Acquisition](https://longbridge.com/zh-CN/news/278778570.md)